Physician profile
Jay St John
NPI 1578820619
$349.78
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $39.98.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $64.72 | 2019 | |
| Gilead Sciences, INC. | $39.98 | 2020 | |
| Abbvie INC. | $39.29 | 2019 | |
| Novo Nordisk INC | $33.95 | 2019 | |
| Glaxosmithkline, LLC. | $31.65 | 2019 | |
| Merck Sharp & Dohme LLC | $26.30 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $21.47 | 2019 | |
| Seqirus USA INC | $14.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.31 | 2019 | |
| Smith+Nephew, INC. | $14.03 | 2019 | |
| Shire North American Group INC | $13.39 | 2019 | |
| Genentech USA, INC. | $12.67 | 2019 | |
| Electromed, INC. | $12.16 | 2019 | |
| Lilly USA, LLC | $11.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay St John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.